DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Blue Ridge Bankshares, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / January 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Blue Ridge Bankshares, Inc. (“Blue Ridge” or “the Company”) (N…

LOS ANGELES, CA / ACCESSWIRE / January 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Blue Ridge Bankshares, Inc. ("Blue Ridge" or "the Company") (NYSE American:BRBS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s securities between March 10, 2023 and October 31, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before February 5, 2024.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at bschall@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Blue Ridge’s financial statements from March 10, 2023, to the present contained errors. The Company would be forced to restate its earnings for periods between March 10, 2023, and October 31, 2023. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Blue Ridge, investors suffered damages.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com

SOURCE: The Schall Law Firm

View the original press release on accesswire.com

Total
0
Shares
Previous Article

Mary Kay Helps Pioneer Gender Equality Research in Algorithms and Artificial Intelligence

Next Article

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Entergy Corporation and Encourages Investors to Contact the Firm

Related Posts

Pylontech’s ESS Helps Japan Reach its “Beyond Zero” Carbon Goals

SHANGHAI, Feb. 22, 2022 /PRNewswire/ — Pylon Technologies Co., Ltd. (hereinafter referred to as “Pylontech”) recently obtained Japanese S-Mark certificate based on the JIS C 8715-2:2019 test standard from TÜV Rheinland Japan, an authoritative in-country certification body. Following the 37Ah energy storage cell (model: 37PN) passing the earthquake protection test earlier, Pylontech obtained Japanese S-Mark certification […]

‫شبكة تلفزيون الصين الدولية (CGTN): الصين تضفي حيوية على حماية التنوع البيولوجي العالمي

بكين، 17 ديسمبر 2022 / PRNewswire / — يمكن قياس أهمية التنوع البيولوجي في التنمية البشرية من خلال حقيقة أن أكثر من نصف الناتج المحلي الإجمالي في العالم يأتي من الموارد الطبيعية وأن معيشة أكثر من 3 مليارات شخص تعتمد على التنوع البيولوجي البحري والساحلي. ومع ذلك، فإن النظام الإيكولوجي للأرض معرض للخطر حيث تُظهر […]

Terran Biosciences and University of Maryland, Baltimore announce exclusive licensing deal for a portfolio of patents and data supporting novel innovation in the psychedelic therapeutic space

NEW YORK, March 8, 2022 /PRNewswire/ — Terran Biosciences, Inc. (“Terran”) has entered into an agreement with the University of Maryland, Baltimore (“UMB”) for a worldwide exclusive license to develop and commercialize a portfolio of UMB’s patents and data to support a novel approach to the treatment of neurological and psychiatric illnesses with psychedelic therapeutics. […]

‫ MGEX لتوفير التسوية كخدمة لتبادل الطب الذكي (IMX)™

مينيابوليس و شيكاغو 23 يونيو 2022 /PRNewswire/ Minneapolis Grain Exchange (MGEX™) — ، وسوق العقود المعينة ( DCM ) ومنظمة تسوية المشتقات ( DCO ) و Intelligent Medicine Exchange (IMX)™ ، مطور أول سوق آجل مخصص على أساس جوانب متعددة من اقتصاد الرعاية الصحية، أعلن اليوم أنهم أبرموا اتفاقية لشركة MGEX لتقديم خدمات التسوية إلى IMX لعقود مستقبلية وخيارات معينة مسددة نقدًا في العقود الآجلة. وستشمل الخدمات إدارة […]